1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL
Market cap: $113.6M (2/08/2026)
Price: $3.66
Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Material disclosure
Announce FDA Acceptance of CUTX-101 NDA Resubmission
Other Events
Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Announce an Update on the NDA for CUTX-101
Earnings Release
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)
Post-Effective Amendment to Registration Statement